WEST PORT, Conn., and SCOTTSDALE, Ariz., May 7 /PRNewswire/ -- Advanced BioHealing, Inc. (ABH) and Regenesis Biomedical, Inc. announced today an agreement focused on the promotion of Dermagraft(R) within the United States (US) government healthcare system. Under terms of the agreement Regenesis will provide its specialized sales force to market ABH’s product Dermagraft within the Veteran’s Administration (VA), Department of Defense (DOD), and TriCare healthcare payer systems.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)
“Since launching Dermagraft in 2007, we have seen the need for a focused commercial presence within government healthcare systems,” said Kevin Rakin, Chairman and CEO of Advanced BioHealing. “The management team at Regenesis has developed a corporate competency in promoting and distributing advanced wound care technology within these systems. We believe this co-promotion is the most effective way to maximize reach and penetration of Dermagraft in this specialized market.”
Dermagraft is a bioengineered tissue product approved by the Food and Drug Administration (FDA) for the treatment of diabetic foot ulcers (DFUs). DFUs, a complication of diabetes, affect more than 400,000 people every year in the US. If not treated properly, DFUs can result in serious infection, sometimes resulting in the need for partial or full limb amputation. There are over 100,000 amputations performed annually in the US with more than 80% owing their origin to uncontrolled infection.
“There are many wound care companies that would enjoy the opportunity to promote a product like Dermagraft,” says Virginia Rybski, Acting President of Regenesis Biomedical. “ABH has done a tremendous job in promoting the product in the traditional out-patient environment. We are pleased to have the opportunity for our sales and marketing team to bring this complementary product to veterans and soldiers who will benefit from treatment of their diabetic wounds.” There are more than one hundred VA and DOD medical facilities within the US. They range in treatment capability from tertiary out-patient care for military veterans and soldiers to full service in-patient facilities.
Regenesis developed and now markets the Provant(R) Wound Therapy System. Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis’ proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics. For more information about Regenesis Biomedical visit http://www.Regenesisbiomedical.com
About Advanced BioHealing, Inc.
Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft, for diabetic foot ulcers. Additionally, the Company’s development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with corporate offices in West Port, CT and manufacturing operations in La Jolla, CA. For more information about ABH visit http://www.AdvancedBioHealing.com
CONTACT: Dean Tozer, VP Marketing & Corporate Development of Advanced
BioHealing, Inc., +1-615-260-3770, DTozer@AdvancedBioHealing.com; or Media,
Scott Robey, VP Marketing, robey@regenesisbiomedical.com, or Clinicians,
Rick Isenberg, MD, VP Clinical Affairs, isenberg@regenesisbiomedical.com,
or Investors, Virginia Rybski, Acting President,
rybski@regenesisbiomedical.com, all of Regenesis Biomedical, Inc.,
+1-480-970-4970
Web site: http://www.regenesisbiomedical.com/
http://www.AdvancedBioHealing.com/
http://www.Dermagraft.com/
